OBJECTIVE:To assess clinical value of modified Shenling Baizhu powder(加味参苓白术散,SBP)in intervening targeted therapy-induced diarrhea.METHODS:This study was a prospective randomized controlled study.Eighty-five no...OBJECTIVE:To assess clinical value of modified Shenling Baizhu powder(加味参苓白术散,SBP)in intervening targeted therapy-induced diarrhea.METHODS:This study was a prospective randomized controlled study.Eighty-five non-small cell lung cancer(NSCLC)patients with diarrhea who took targeted drugs were randomly divided into two groups.The experimental group received modified SBP,while the control group received imodium.During 2 courses of treatment(1 week/course)and 2 weeks of follow-up,we observed remission and recurrence of diarrhea,as well as the improvement of Karnofsky score(KPS)in the two groups and drug safety.RESULTS:Eighty cases were completed,with 40 cases in the experimental group and 40 cases in the control group.The control group's diarrhea remission rate was significantly lower than the experimental group's(P<0.05).After 2 courses of treatment,the symptom scores of both groups were lower than before,with that of the experimental group remarkably lower(P<0.05).Furthermore,the experimental group experienced less abdominal fullness and appetite loss than the control group(P<0.05).There was no prominent difference in overall diarrhea recurrence,time,or KPS after treatment between the two groups(P>0.05).No unique adverse events occurred in experimental group or control group.CONCLUSION:The modified SBP could improve targeted therapy-induced diarrhea in NSCLC,and is superior to imodium in relieving diarrhea,improving related symptom scores and symptoms,with no obvious drug-related adverse events.展开更多
基金Clinical Study of Shenling Baizhu Powder Flavoring Intervention on Diarrhea Associated with Targeted Treatment of Non-small Cell Lung Cancer,Zhejiang Science and Technology Program of Traditional Chinese Medicine(2022ZA151)。
文摘OBJECTIVE:To assess clinical value of modified Shenling Baizhu powder(加味参苓白术散,SBP)in intervening targeted therapy-induced diarrhea.METHODS:This study was a prospective randomized controlled study.Eighty-five non-small cell lung cancer(NSCLC)patients with diarrhea who took targeted drugs were randomly divided into two groups.The experimental group received modified SBP,while the control group received imodium.During 2 courses of treatment(1 week/course)and 2 weeks of follow-up,we observed remission and recurrence of diarrhea,as well as the improvement of Karnofsky score(KPS)in the two groups and drug safety.RESULTS:Eighty cases were completed,with 40 cases in the experimental group and 40 cases in the control group.The control group's diarrhea remission rate was significantly lower than the experimental group's(P<0.05).After 2 courses of treatment,the symptom scores of both groups were lower than before,with that of the experimental group remarkably lower(P<0.05).Furthermore,the experimental group experienced less abdominal fullness and appetite loss than the control group(P<0.05).There was no prominent difference in overall diarrhea recurrence,time,or KPS after treatment between the two groups(P>0.05).No unique adverse events occurred in experimental group or control group.CONCLUSION:The modified SBP could improve targeted therapy-induced diarrhea in NSCLC,and is superior to imodium in relieving diarrhea,improving related symptom scores and symptoms,with no obvious drug-related adverse events.
